Novo Nordisk reported first-quarter group revenue of 96.8 billion Danish kroner — about $15.2 billion — up 32 percent at constant exchange rates. [4] Wegovy pill sales came in at 2.26 billion kroner, nearly double the 1.16-billion-kroner consensus that Reuters had compiled from analyst polls — a roughly 95 percent beat against the line item analysts were watching most closely. [1] [3] The pill, launched January 5, recorded 1.3 million U.S. prescriptions in the quarter and more than two million cumulative since launch. [1] [3] CEO Mike Doustdar told CNBC the brand now commands 65 percent of all new obesity prescriptions written in the United States and called the print "a turnaround situation." [2] [4] The company raised full-year guidance to a decline of 4 to 12 percent at constant exchange rates, from a previous 5 to 13 percent. [3] Novo's Copenhagen-listed shares rose as much as 8 percent on the open and were trading 6.7 percent higher in morning European trade. [4]
The numerator is the news. The denominator is what matters. The paper has spent two days reading the GLP-1 thread in clinical and demographic terms — Tuesday's note that the Wegovy pill had hit 113,000 weekly scripts as Foundayo's first month rolled out modestly, and the same day's read of a 100,000-person GLP-1 cohort showing depression down 44 percent. What Wednesday's print confirms is that the addressable population is no longer theoretical. It is filling prescriptions.
The structural disclosure inside the earnings release is not the topline. It is the channel. More than half of U.S. Wegovy sales now come through lower-priced self-pay channels — up from "just over 10 percent a year ago," according to Novo's earnings statement. [3] One year ago obesity treatment was a benefits-coverage problem. Today it is a consumer category. Doustdar told reporters on a media call that the company has found a "sweet spot" with pricing. The starting dose of the Wegovy pill costs $149 a month at retail; higher doses run $299 to $399. Direct-to-consumer telehealth — Ro, LifeMD, WeightWatchers, Hims & Hers (now selling FDA-approved doses after a March agreement) — carries the bulk of the volume.
The clinical implication of the channel shift deserves its own attention. When 80 percent of new pill patients are GLP-1-naive, as Doustdar told CNBC's Charlotte Reed Wednesday, the treatment is reaching people the old injection model had not. The five U.S. patients CNBC interviewed in April said they had held off on injections because of fear of needles or out-of-pocket cost. The pill removed both barriers. The patient population now starting therapy is the cohort the obesity-medicine literature has been calling "untreated obesity" for two decades — about 100 million Americans by CDC criteria. The launch metrics suggest, for the first time, what penetration into that population looks like under cash-pay rules.
The competition matters less than the headline framing implies, but the window has changed. Eli Lilly's oral weight-loss drug Foundayo (orforglipron) won FDA approval April 1 under the Commissioner's National Priority Voucher pilot — closing the only-pill window Novo had to itself for roughly twelve weeks. Lilly disclosed in late April that more than 20,000 people have started Foundayo, with about 1,000 starting daily and 80 percent new to GLP-1 — the same demographic Novo is reaching. Doustdar said Wednesday that Foundayo's launch has not affected the Wegovy pill's trajectory: "We have now been competing with our competitor for about a month — and so far, so good." [4] Both companies are now reporting strong volumes from new-to-class patients. The market is expanding faster than either is taking share — but the next print, the one that lands after a full quarter of head-to-head competition, will be the one that tests whether the 65 percent of new starts is a launch artifact or a structural lead.
The injection portfolio adds nuance. Wegovy injection sales rose 12 percent year-on-year to 18.2 billion kroner — slightly below LSEG expectations. Novo Nordisk launched the higher-dose Wegovy HD (semaglutide 7.2 mg) in April, which delivered 20.7 percent mean weight loss in the STEP UP trial — comparable to Lilly's Zepbound. The pill is not cannibalizing the shot; CFO Karsten Munk Knudsen told reporters they are not seeing significant patient drop-offs. Novo, in other words, has built a portfolio across formulations and price points. Doustdar's framing on the earnings call: Wegovy pill is "the only oral peptide for the treatment of obesity," defining a category.
What the print does not yet contain is anything definitive about psychiatric labeling. The 95,000-person within-person Swedish cohort that the paper covered Tuesday — semaglutide associated with a 44 percent reduction in depression incidence and a 47 percent reduction in substance-use disorder — is bound for Lancet Psychiatry. If those signals replicate, the FDA will face the question of how to label a class that was approved for one indication and is now demonstrating effects across mental health, addiction, and possibly cognition. The 1.3 million prescriptions in three months mean the post-marketing surveillance pool is already large enough to detect rare adverse events. It is also large enough to detect rare benefits.
Two structural questions extend past the quarter. The first: what happens to PBM contracts when more than half of a category's sales bypass the traditional benefits architecture? Express Scripts, Caremark, and OptumRx have built their negotiating leverage on covered-life concentration. A self-pay-dominant market is one where the PBM is the cost-of-entry, not the gatekeeper. Industry attorneys have warned that the channel shift will eventually trigger a DOJ or FTC inquiry into rebate structures. None has surfaced. The second: European launches arrive in the second half of 2026 — Novo has filed with the EMA and other regulators. The pill is the only oral GLP-1 in obesity in Europe at the point of launch. The U.S. launch is the dress rehearsal for a European market that is structurally different — single-payer health systems, lower self-pay rates, and obesity prevalence that has lagged the U.S. by about a decade.
The Wegovy injection class arrived in 2021 as a clinical phenomenon. Four years later, the oral version is arriving as a commercial one. The Q1 print does not tell us what the long-term population-level effects of putting 100 million Americans on a peptide will be. It does tell us that the question is no longer hypothetical. The kitchen counter is where this drug now lives. The company's adjusted operating profit was 32.86 billion Danish crowns ($5.16 billion) — well above the 28.74-billion-crown consensus — and the guidance raise (a full-year decline of 4 to 12 percent rather than 5 to 13 percent) is the formal management acknowledgment that the trajectory has bent. [3] [4] Doustdar said the goal for the year is to "expand the U.S. market." It is already expanding. The question for the rest of 2026 is what arrives second.
-- NORA WHITFIELD, Chicago